Skip to content

Berberine, Chlorogenic Acid and Tocotrienols in Menopause-associated Dyslipidemia

Nutraceutical Intervention With Berberine, Chlorogenic Acid and Tocotrienols for Menopause-associated Dyslipidemia: a Randomized, Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03019263
Enrollment
63
Registered
2017-01-12
Start date
2017-03-31
Completion date
2018-01-12
Last updated
2025-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Brief summary

Menopause is usually associated with an increase in body weight, a change in body composition and fat distribution and a large number of cardio-metabolic changes, such as hypertension, reduction of insulin-sensitivity and dyslipidaemia. The first-line strategy for these complications is the modification of dietary habits and lifestyle in terms of physical activity. Besides, there is also a growing interest in complementary therapies (i.e. nutraceuticals) that can be used alone or in combination to achieve more consistent results. In this context, preliminary evidence supports the potential role of some compounds of vegetal origin such as berberine, chlorogenic acid and tocotrienols. However, in support of their use, the evidence from good quality trials is limited.

Interventions

DIETARY_SUPPLEMENTNutraceutical

Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid

OTHERControl

Nutritional counseling

Sponsors

University of Pavia
CollaboratorOTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* LDL cholesterol \>100 mg/dL * Written informed consent available

Exclusion criteria

* Use of any drug affecting blood lipids * Hormone replacement therapy * Adherence to a weigh loss diet in the previous 6 months * Cancer diagnosis * Known thyroid, liver, renal or muscle diseases * Any medical or surgical condition which could lead to an inconstant adhesion to the protocol

Design outcomes

Primary

MeasureTime frameDescription
LDL cholesterol3 monthsLDL cholesterol

Secondary

MeasureTime frameDescription
Total cholesterol3 monthsTotal cholesterol
HDL cholesterol3 monthsHDL cholesterol
Blood glucose3 monthsBlood glucose
Serum Insulin3 monthsSerum Insulin
Insulin resistance3 monthsHomeostatic model assessment (HOMA index)
Fat distribution3 monthsWaist circumference
Fat Mass3 monthsFat Mass
Menopausal symptoms3 monthsGreene Climacteric Scale
Quality of life3 months36-Item Short Form Health Survey (SF-36)
Body weight3 monthsBody weight

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026